Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ERCC2
REST API REST API
Homo sapiens
ERCC2 is differentially expressed in 245 experiments: 98 organism parts: liver, pancreas, ... (96 more);, 164 disease states: normal, Burkitt's lymphoma, ... (162 more);, 68 cell types 316 cell lines 23 compound treatments and 62 other conditions.
Synonyms XPD, MGC102762, MAG, EM9, MGC126218, MGC126219
Orthologs Ercc2 (Mus musculus)   LOC100364929 (Rattus norvegicus)   ercc2 (Danio rerio)   RAD3 (Saccharomyces cerevisiae)   A1L590_BOVIN (Bos taurus)   ENSCING00000003266 (Ciona intestinalis)   ENSCING00000015161 (Ciona intestinalis)   ercc2 (Xenopus laevis)   Q5SBJ3_CANFA (Canis familiaris)   Xpd (Drosophila melanogaster)   (Compare orthologs)
Gene Ontology Term response to UV, response to oxidative stress, DNA binding, nucleotide-excision repair, protein binding, apoptosis, DNA repair, cytoskeleton, cytoplasm, embryonic cleavage, cell proliferation, negative regulation of apoptosis, protein N-terminus binding, chromosome segregation, ATP-dependent helicase activity, metal ion binding, nucleic acid binding, response to hypoxia, mRNA capping, transcription from RNA polymerase II promoter, multicellular organism growth, ATP binding, induction of apoptosis, positive regulation of transcription from RNA polymerase II promoter, RNA polymerase II carboxy-terminal domain kinase activity, spindle, 5'-3' DNA helicase activity, DNA-dependent ATPase activity, nucleus, ATP-dependent DNA helicase activity, aging, iron-sulfur cluster binding, nucleotide binding, post-embryonic development, transcription initiation from RNA polymerase II promoter, protein C-terminus binding, nucleoplasm, cell cycle checkpoint, extracellular matrix organization, positive regulation of transcription, DNA-dependent, protein kinase activity, transcription from RNA polymerase I promoter, hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides, helicase activity, nucleotide-excision repair, DNA incision, viral reproduction, in utero embryonic development, bone mineralization, hair follicle maturation, spinal cord development, transcription-coupled nucleotide-excision repair, cyclin-dependent protein kinase activating kinase holoenzyme complex, positive regulation of DNA binding, holo TFIIH complex, gene expression, UV protection, hair cell differentiation, interspecies interaction between organisms, skin development, transcription initiation from RNA polymerase I promoter, hydrolase activity, acting on acid anhydrides, hemopoietic stem cell differentiation, hair cycle process, erythrocyte maturation, positive regulation of viral transcription, SSL2-core TFIIH complex, central nervous system myelin formation, protein phosphorylation, termination of RNA polymerase I transcription, nucleotide-excision repair, DNA damage removal, transcription elongation from RNA polymerase II promoter, MMXD complex, transcription elongation from RNA polymerase I promoter, nucleobase-containing compound metabolic process
InterPro Term DEAD_2, DNA_helicase_DNA-repair_Rad3, DUF1227, Helicase_ATP-dep_c2, Helicase-like_DEXD_c2, SNF2_N, XPGD_DNA_repair, Helic_SF1/SF2_ATP-bd_DinG/Rad3
UniProt Accession P18074, Q7KZU6, A8MX75, B4E0F6, E7EVE9, E9PM96
Gene-Disease Assocation XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP D; XPD, TRICHOTHIODYSTROPHY, PHOTOSENSITIVE; TTDP, CEREBROOCULOFACIOSKELETAL SYNDROME 2; COFS2
Search EB-eye ENSG00000104884
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (37 experiments)

Factor Value U/D Experiments
A549
2
E-GEOD-6013, E-GEOD-3202
BT-474
2
E-GEOD-3529, E-GEOD-5823
BT474
2
E-MTAB-62, E-MEXP-440
MCF-7
2
E-GEOD-5823, E-GEOD-3529
SW1783
1
E-MTAB-37
SW1990
1
E-MTAB-37
310 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, ... (39 experiments)

Factor Value U/D Experiments
endothelial cell
2
E-GEOD-96, E-GEOD-3920
monocyte
2
E-GEOD-11755, E-GEOD-22373
CD4+ T cell
1
2
5
E-GEOD-16190, E-MTAB-25, E-MTAB-24
721 B lymphoblast
1
1
E-AFMX-5
liver cancer
1
E-GEOD-21154
eosinophil
1
E-GEOD-3982
62 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-25, E-GEOD-2508, E-GEOD-1869, ... (45 experiments)

Factor Value U/D Experiments
lung carcinoma
2
E-GEOD-6014, E-MTAB-37
acute lymphoblastic leukemia
2
E-MTAB-62, E-GEOD-96
Burkitt's lymphoma
1
2
E-MTAB-37, E-GEOD-96, E-GEOD-1880
acute promyelocytic leukemia
1
2
E-MTAB-62, E-GEOD-995, E-GEOD-96
adenomyosis
1
E-GEOD-7307
dedifferentiated chondrosarcoma
1
E-MTAB-62
158 more value(s).


Compound treatment

studied in E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-GEOD-3720, E-TABM-868, ... (17 experiments)

Factor Value U/D Experiments
none
3
5
E-GEOD-5824, E-GEOD-412, E-MEXP-1958, E-TABM-868, E-GEOD-20719, ... (8 experiments)
ethanol
2
E-MEXP-2241, E-GEOD-3113
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
LDL
1
1
E-GEOD-5741
MIG control
1
1
E-GEOD-15811
interferon alpha
1
E-GEOD-1740
17 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-2191, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-22148, E-TABM-147, E-GEOD-21138

Environmental stress
studied in E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-GEOD-1923, E-TABM-1029, E-GEOD-2466, E-GEOD-21750, E-MEXP-421, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-MEXP-1220, E-GEOD-5681, E-GEOD-20540, E-GEOD-20504, ... (10 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-GEOD-16363, E-GEOD-430, ... (28 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980 ... (5 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-17636

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

RNAi
studied in E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541

Processing time: 0.353 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM